These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15243108)

  • 1. Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital.
    Yan JJ; Ko WC; Wu JJ; Tsai SH; Chuang CL
    J Clin Microbiol; 2004 Jul; 42(7):3329-32. PubMed ID: 15243108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia.
    Memon JI; Rehmani RS; Ahmed MU; Elgendy AM; Nizami IY
    Saudi Med J; 2009 Jun; 30(6):803-8. PubMed ID: 19526164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.
    Rodríguez-Baño J; Alcalá J; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    J Antimicrob Chemother; 2009 Apr; 63(4):781-4. PubMed ID: 19223299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors.
    Ozgunes I; Erben N; Kiremitci A; Kartal ED; Durmaz G; Colak H; Usluer G; Colak E
    Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital.
    Briñas L; Lantero M; de Diego I; Alvarez M; Zarazaga M; Torres C
    J Antimicrob Chemother; 2005 Dec; 56(6):1107-10. PubMed ID: 16239288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases.
    Lavigne JP; Blanc-Potard AB; Bourg G; Moreau J; Chanal C; Bouziges N; O'callaghan D; Sotto A
    Clin Microbiol Infect; 2006 Dec; 12(12):1199-206. PubMed ID: 17121626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients.
    Peña C; Gudiol C; Tubau F; Saballs M; Pujol M; Dominguez MA; Calatayud L; Ariza J; Gudiol F
    Clin Microbiol Infect; 2006 Mar; 12(3):279-84. PubMed ID: 16451416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.
    Laupland KB; Church DL; Vidakovich J; Mucenski M; Pitout JD
    J Infect; 2008 Dec; 57(6):441-8. PubMed ID: 18990451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon.
    Kanafani ZA; Mehio-Sibai A; Araj GF; Kanaan M; Kanj SS
    Am J Infect Control; 2005 Aug; 33(6):326-32. PubMed ID: 16061138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology.
    Rodríguez-Baño J; López-Cerero L; Navarro MD; Díaz de Alba P; Pascual A
    J Antimicrob Chemother; 2008 Nov; 62(5):1142-9. PubMed ID: 18641033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.